New drug combo for rare bone marrow cancer shows early promise, but trial halted
NCT ID NCT06245941
First seen Jan 11, 2026 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This study tested a combination of two experimental drugs, TQ05105 and TQB3909, in 21 adults with moderate- to high-risk myelofibrosis, a rare bone marrow cancer. The goal was to see if the combination could safely shrink an enlarged spleen and improve symptoms. However, the trial was terminated early, so the full results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hennan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
People's Hospital of Tianjin
Tianjin, Tianjin Municipality, 300122, China
-
The First Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, 310003, China
-
The Second People's Hospital of Hefei
Hefei, Anhui, 230012, China
-
Xijing Hospital of the Fourth Military Medical University
Xi'an, Shaanxi, 710032, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQ05105 tablets (a JAK1/JAK2 inhibitor) and TQB3909 tablets (a BCL-2 inhibitor)
What this could lead to
If successful, this combination could offer a new treatment option to reduce spleen size and control symptoms in people with moderate- to high-risk myelofibrosis.
What could go wrong
The trial was terminated early, so results are limited. It was a small, early-phase study (phase 1/2) with only 21 participants, so any benefits or risks are not well understood.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.